A detailed history of Keene & Associates, Inc. transactions in Pfizer Inc stock. As of the latest transaction made, Keene & Associates, Inc. holds 112,002 shares of PFE stock, worth $2.9 Million. This represents 2.49% of its overall portfolio holdings.

Number of Shares
112,002
Previous 111,687 0.28%
Holding current value
$2.9 Million
Previous $3.13 Million 3.71%
% of portfolio
2.49%
Previous 2.58%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$27.7 - $31.39 $8,725 - $9,887
315 Added 0.28%
112,002 $3.24 Million
Q2 2024

Aug 09, 2024

SELL
$25.26 - $29.6 $13,488 - $15,806
-534 Reduced 0.48%
111,687 $3.13 Million
Q1 2024

Apr 24, 2024

BUY
$25.89 - $29.73 $1.25 Million - $1.43 Million
48,106 Added 75.03%
112,221 $3.11 Million
Q4 2023

Jan 29, 2024

SELL
$26.13 - $33.94 $100,548 - $130,601
-3,848 Reduced 5.66%
64,115 $1.85 Million
Q3 2023

Oct 13, 2023

BUY
$32.09 - $37.51 $82,503 - $96,438
2,571 Added 3.93%
67,963 $2.25 Million
Q2 2023

Jul 26, 2023

BUY
$36.12 - $41.79 $68,628 - $79,401
1,900 Added 2.99%
65,392 $2.4 Million
Q1 2023

Apr 19, 2023

SELL
$39.39 - $51.28 $7,917 - $10,307
-201 Reduced 0.32%
63,492 $2.59 Million
Q4 2022

Feb 09, 2023

BUY
$41.75 - $54.5 $67,342 - $87,908
1,613 Added 2.6%
63,693 $3.26 Million
Q3 2022

Nov 01, 2022

SELL
$43.76 - $53.42 $124,716 - $152,247
-2,850 Reduced 4.39%
62,080 $2.72 Million
Q2 2022

Jul 21, 2022

BUY
$46.53 - $55.17 $5,816 - $6,896
125 Added 0.19%
64,930 $3.4 Million
Q1 2022

Apr 12, 2022

SELL
$45.75 - $56.69 $30,789 - $38,152
-673 Reduced 1.03%
64,805 $3.36 Million
Q4 2021

Jan 31, 2022

BUY
$41.32 - $61.25 $2.71 Million - $4.01 Million
65,478 New
65,478 $3.87 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $145B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Keene & Associates, Inc. Portfolio

Follow Keene & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keene & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Keene & Associates, Inc. with notifications on news.